• Pivotal ABX464 clinical trials ongoing or planned for three indications: Ulcerative colitis, Crohn’s disease and Covid-19

• Four phase 1 studies are being initiated to generate complementary data to support the late-stage development program of ABX464

• Discussions planned with regulatory agencies in Europe, the US and Japan to seek recommendations and agreement with the phase 3 development approach in ulcerative colitis and Crohn’s disease

• Development and upscaling of ABX464 manufacturing is ongoing to meet phase 3 needs and potential commercialization, in preparation of a possible positive Covid-19 trial outcome